Kroemer Guido
J Clin Invest. 2015 Jan;125(1):1-4. doi: 10.1172/JCI78652. Epub 2015 Jan 2.
Autophagy ("self-eating") constitutes one of the most spectacular yet subtly regulated phenomena in cell biology. Similarly to cell division, differentiation, and death, autophagy is perturbed in multiple diseases, in that excessive or deficient autophagy may contribute to pathogenesis. Numerous attempts have been launched to identify specific inducers or inhibitors of autophagy and to use them for the therapeutic correction of its deregulation. At present, several major disease categories (including but not limited to age-related, cardiovascular, infectious, neoplastic, neurodegenerative, and metabolic pathologies) are being investigated for pathogenic aberrations in autophagy and their pharmacologic rectification. Driven by promising preclinical results, several clinical trials are exploring autophagy as a therapeutic target.
自噬(“自我吞噬”)是细胞生物学中最引人注目的现象之一,但其调控却十分精细。与细胞分裂、分化和死亡类似,自噬在多种疾病中都会受到干扰,过度或不足的自噬都可能导致发病机制的改变。人们已经进行了大量尝试来寻找自噬的特异性诱导剂或抑制剂,并将其用于治疗自噬失调的情况。目前,正在研究几种主要疾病类别(包括但不限于与年龄相关的、心血管的、感染性的、肿瘤性的、神经退行性的和代谢性疾病)中自噬的致病性异常及其药物纠正。在有前景的临床前结果的推动下,几项临床试验正在探索将自噬作为治疗靶点。